CXCL9 and ovarian carcinoma: GSK126, restores CD8 cell cytotoxicity (164).Combination of EZH2 and DNMT inhibitors synergistically increased IFN-γ responsiveness and CXCL9 and CXCL10 expression and shrinks tumor size during immunotherapy in ovarian cancer cell lines (165).EZH2 knockdown or pharmacologic inhibition restoring IFN-γ-induced gene expression in various cancers (157–160).